Informations générales (source: ClinicalTrials.gov)
Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France (FAST)
Interventional
Phase 4
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba (Voir sur ClinicalTrials)
novembre 2019
décembre 2021
29 juin 2024
Evaluation of antiretroviral treatment adherence using determination of Bictegravir,
Emtricitabine and Tenofovir with new HIV patients in France
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL FOCH | DAVID ZUCMAN | 05/05/2025 07:12:03 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital Bichat | Zélie ZJ JULIA | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Henri Mondor-Albert Chenevier | Jean-Daniel JDL LELIEVRE, MD | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Necker-Enfants Malades | Fatima FT TOUAM | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Raymond Poincaré | Morgane HB MARCOU | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Saint Antoine | Christian CT TRAN | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Tenon | Anne AA ADDA | Contact (sur clinicalTrials) | |||
| CENTRE HOSPITALIER SUD FRANCILIEN | Nouara NA AGHER | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hopital Bretonneau - 37044 - Tours - France | Olivier OB BOURGAULT | Contact (sur clinicalTrials) | |||
| Hôpital Côte de Nacre - Service des Maladies Infectieuses - 14033 - Caen - France | Renaud RV VERDON, MD, PhD | Contact (sur clinicalTrials) | |||
| Hopital Francois Mitterrand - 21034 - Dijon - France | Sandrine SG GOHIER | Contact (sur clinicalTrials) | |||
| Hôpital Gui de Chauliac - Service de Maladies Infectieuses et Tropicales - 34000 - Montpellier - France | Jacques REYNES, MD, PhD | Contact (sur clinicalTrials) | |||
| Hopital Gustave Dron - 59208 - Tourcoing - France | Sylvie SV VANDAMME | Contact (sur clinicalTrials) | |||
| Hôpital Pellegrin - Service de Médecine Interne et Maladies Infectieuses - 33000 - Bordeaux - France | SEVERINE SL LE PUIL | Contact (sur clinicalTrials) | |||
| Hopital Zobda Quitman - 97261 - Fort-de-france - Martinique - France | André AC CABIE, PhD | Contact (sur clinicalTrials) | |||
| L'ARCHET - 06200 - Nice - France | Ghaleb GZ ZOUZOU | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hopital Sainte-Marguerite - 13274 - Marseille - France | Caroline CD DEBREUX | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- age > 18 years
- newly diagnosed HIV-infected individual evidenced by any of the following tests: (i)
positive self-test, (ii) positive HIV Rapid antibody test, (iii) positive HIV
immunoassay (ELISA 4th generation) test
- antiretroviral-treatment naive
- negative urine pregnancy test for women of childbearing potential and willing to use
effective contraception (mechanical or medicamental)
- willing to sign an informed written consent-
- regular health insurance
- willing to provide two distinct contact information (telephone number and/or email)
in order to be easily reached if needed between Day 0 and Day 7
- age > 18 years
- newly diagnosed HIV-infected individual evidenced by any of the following tests: (i)
positive self-test, (ii) positive HIV Rapid antibody test, (iii) positive HIV
immunoassay (ELISA 4th generation) test
- antiretroviral-treatment naive
- negative urine pregnancy test for women of childbearing potential and willing to use
effective contraception (mechanical or medicamental)
- willing to sign an informed written consent-
- regular health insurance
- willing to provide two distinct contact information (telephone number and/or email)
in order to be easily reached if needed between Day 0 and Day 7
- clinical symptoms suggestive of opportunistic infections
- participant not willing to provide two distinct contact information
- a woman who is pregnant or breast-feeding or planning to become pregnant during the
expected study period.
- Co-medication with deleterious interaction with study treatment (eg enzyme inducer)